阿斯利康重磅高血压新药 III 期成功

Insight数据库2025-07-14

7 月 14 日，阿斯利康宣布，Baxdrostat 在针对未控制或难治性高血压患者的BaxHTN III 期临床试验中，达到了主要终点和所有次要终点。来源：阿斯利康官网BaxHTN 是一项多中心、随机、双盲、安慰剂对照、平行分组的 III 期研究，旨在评估Baxdrostat对于使用两种不同抗高血压药物治疗的未控制高血压患者和使用三种或更多种不同抗高血压药物（其中一种是利尿剂）治疗的难治性高血压...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2551723469?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-14 14:32","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2551723469","market":"us","top_or_hot":-1,"title":"阿斯利康重磅高血压新药 III 期成功","media":"Insight数据库","content":"<div>\n<p>7 月 14 日，阿斯利康宣布，Baxdrostat 在针对未控制或难治性高血压患者的BaxHTN III 期临床试验中，达到了主要终点和所有次要终点。来源：阿斯利康官网BaxHTN 是一项多中心、随机、双盲、安慰剂对照、平行分组的 III 期研究，旨在评估Baxdrostat对于使用两种不同抗高血压药物治疗的未控制高血压患者和使用三种或更多种不同抗高血压药物（其中一种是利尿剂）治疗的难治性高血压...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714143828a44921de&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>阿斯利康重磅高血压新药 III 期成功</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n阿斯利康重磅高血压新药 III 期成功\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-14 14:32 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714143828a44921de&s=b><strong>Insight数据库</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>7 月 14 日，阿斯利康宣布，Baxdrostat 在针对未控制或难治性高血压患者的BaxHTN III 期临床试验中，达到了主要终点和所有次要终点。来源：阿斯利康官网BaxHTN 是一项多中心、随机、双盲、安慰剂对照、平行分组的 III 期研究，旨在评估Baxdrostat对于使用两种不同抗高血压药物治疗的未控制高血压患者和使用三种或更多种不同抗高血压药物（其中一种是利尿剂）治疗的难治性高血压...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714143828a44921de&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2456880835.USD","symbol_name":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714143828a44921de&s=b","article_id":"2551723469","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714143828a44921de&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2551723469","pubTimestamp":1752474726,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"7 月 14 日，阿斯利康宣布，Baxdrostat 在针对未控制或难治性高血压患者的BaxHTN III 期临床试验中，达到了主要终点和所有次要终点。2023 年 2 月，阿斯利康 18 亿美元收购CinCor，囊获了该产品。目前，Baxdrostat 正在开展高血压、心力衰竭等多个适应症的临床。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","BK4568":"美国抗疫概念","BK4585":"ETF&股票定投概念","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","III":"信息服务","AZN":"阿斯利康","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1829250122.USD":"高盛欧洲核心股票组合Acc","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","BK4134":"信息科技咨询与其它服务","BK4007":"制药","BK4588":"碎股"},"translate_title":"AstraZeneca's blockbuster new hypertension drug successfully phase III","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":1,"III":1},"content_text":"7 月 14 日，阿斯利康宣布，Baxdrostat 在针对未控制或难治性高血压患者的BaxHTN III 期临床试验中，达到了主要终点和所有次要终点。来源：阿斯利康官网BaxHTN 是一项多中心、随机、双盲、安慰剂对照、平行分组的 III 期研究，旨在评估Baxdrostat对于使用两种不同抗高血压药物治疗的未控制高血压患者和使用三种或更多种不同抗高血压药物（其中一种是利尿剂）治疗的难治性高血压患者的安全性、耐受性和疗效。结果显示，与安慰剂组相比，两种剂量的 Baxdrostat（2 mg 和 1 mg）在 12 周时均显著降低了平均坐位收缩压(SBP)。该研究还成功达到了所有次要终点，总体耐受性和安全性良好。具体数据将在 2025 年 8 月欧洲心脏病学会(ESC)大会公布。Baxdrostat 是一种高选择性醛固酮合成酶抑制剂，可抑制催化胆固醇合成醛固酮最后步骤的 CYP11B2 酶（也称为醛固酮合酶），进而抑制醛固酮的合成来降低醛固酮的水平，且不降低皮质醇水平。2023 年 2 月，阿斯利康 18 亿美元收购CinCor，囊获了该产品。目前，Baxdrostat 正在开展高血压、心力衰竭等多个适应症的临床。来源：Insight 数据库","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2551723469","isCrawlerRequest":true}